Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posseltinib in relapsed/refractory non-Hodgkin's lymphoma
NCT07114367Phase 1Recruiting
- Sponsor
- NOBO Medicine
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of poseltinib in follicular lymphoma (FL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), sponsored by NOBO Medicine. Primary endpoints: Maximum Tolerated Dose or Optimal Biological Dose at 48 months and Adverse Events at 48 months. Started Dec 2025; status: recruiting.
02
Drugs
poseltinib
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07114367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114367.